Molecular evolution of specific human antibody against muc1 mucin results in improved recognition of the antigen on tumor cells

Tumor Biology

Volumn 30, Issue 4, 2009, Pages 221-231

  Persson, Jonas ^a   Bäckström, Malin ^b   Johansson, Henrik ^a   Jirström, Karin ^c   Hansson, Gunnar C ^b   Ohlin, Mats ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Antibody; Molecular evolution; MUC1; Phage display; Specificity fine tuning

Indexed keywords

MUCIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM REPEAT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, GEL; CRICETINAE; CRICETULUS; EPITOPES; EVOLUTION, MOLECULAR; FEMALE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUCIN-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; REFERENCE VALUES; REPETITIVE SEQUENCES, AMINO ACID; T-LYMPHOCYTES;

EID: 70349250523     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000240634     Document Type: Article

References (44)

1. Hilkens J, Kroezen V, Bonfrer JM, De Jong- Bakker M, Bruning PF: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 1986; 46: 2582-2587.
2. Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339-353.
3. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286-15293.
4. Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990; 265: 5573-5578.
5. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, Keydar I: Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 1990; 189: 463-473.
6. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S: Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999; 59: 5464-5470.
7. Hanisch FG, Stadie TR, Deutzmann F, PetERβKatalinic J: MUC1 glycoforms in breast cancERβcell line T47D as a model for carcinomaassociated alterations of 0-glycosylation. Eur J Biochem 1996; 236: 318-327.
8. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 1995; 233: 607-617.
9. Burchell JM, Mungul A, Taylor-Papadimitriou J: O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001; 6: 355-364.
10. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilkens J, Boer M, Karanikas V, McKenzie IFC, Galanina OE, Simeoni LA, Ter-Grigoryan AG, Belyanchikov IM, Bovin NV, Cao Y, Karsten U, Dai J, Allard WJ, Davis G, Yeung KK, Hanish FG, Lloyd KO, Kudryashov V, Sikut R, Sikut A, Zhang K, Baeckstrom D, Hansson GC, Reis CA, Hassan H, Bennett EP, Claussen H, Norum L, Varaas T, Kierulf B, Nustad K, Ciborowski P, Konitzki WM, Magarian-Blader J, Finn OJ, Hilgers J: Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 1998; 19(suppl 1):1-20.
11. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000; 10: 44-46.
12. Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA: Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti- MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000; 18: 363-370.
13. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006; 24: 571-578.
14. Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends JW, Müllberg J, Hoogenboom HR: A human immunoglobulin G1 antibody originating from an in vitroselected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am J Pathol 2002; 160: 1597-1608.
15. Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, Hilgers JH, Krambovitis E, Arends JW, Hoogenboom HR: Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 1998; 58: 4324-4332.
16. Jirholt P, Borrebaeck CAK, Ohlin M: Antibody evolution from the centre to the periphery: applied to a human antibody fragment recognising the tumour-associated antigen mucin-1. J Mol Biol 2002; 318: 407-416.
17. Jirholt P, Strandberg L, Jansson B, Krambovitis E, Söderlind E, Borrebaeck CAK, Carlsson R, Danielsson L, Ohlin M: A central core structure in an antibody variable domain determines antigen specificity. Protein Eng 2001; 14: 67-74.
18. Wong C, Waibel R, Sheets M, Mach JP, Finnern R: Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol Immunother 2001; 50: 93-101.
19. Persson J, Ohlin M: Antigens for the selection of pan-variable number of tandem repeats motif-specific human antibodies against Mucin-1. J Immunol Methods 2006; 316: 116-124.
20. Engelmann K, Baldus SE, Hanisch FG: Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 2001; 276: 27764-27769.
21. Fowler JC, Teixeira AS, Vinall LE, Swallow DM: Hypervariability of the membrane-associated mucin and cancer marker MUC1. Hum Genet 2003; 113: 473-479.
22. Müller S, Alving K, Peter-Katalinic J, Zachara N, Gooley AA, Hanisch FG: High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. J Biol Chem 1999; 274: 18165-18172.
23. von Mensdorff-Pouilly S, Kinarsky L, Engelmann K, Baldus SE, Verheijen RH, Hollingsworth MA, Pisarev V, Sherman S, Hanisch FG: Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 2005; 15: 735-746.
24. Bäckström M, Link T, Olson FJ, Karlsson H, Graham R, Picco G, Burchell J, Taylor-Papadimitriou J, Noll T, Hansson GC: Recombinant MUC1 mucin with a breast cancerlike O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J 2003; 376: 677-686.
25. Sewell R, Bäckström M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J: The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor associated sialyl Tn O-glycan in human breast cancer. J Biol Chem 2006; 281: 3586-3594.
26. Stanley P: Chinese hamster ovary cell mutants with multiple glycosylation defects for production of glycoproteins with minimal carbohydrate heterogeneity. Mol Cell Biol 1989; 9: 377-383.
27. Kingsley DM, Kozarsky KF, Hobbie L, Krieger M: Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 1986; 44: 749-759.
28. Krambovitis E, Hatzidakis G, Barlos K: Preparation of MUC-1 oligomers using an improved convergent solid-phase peptide synthesis. J Biol Chem 1998; 273: 10874-10879.
29. Söderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Åberg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CAK: Recombinant germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000; 18: 852-856.
30. Ørum H, Andersen PS, Øster A, Johansen LK, Riise E, Bjørnvad M, Svendsen I, Engb: Efficient method for constructing comprehensive murine Fab antibody libraries displayed on phage. Nucleic Acids Res 1993; 21: 4491-4498.
31. Cicortas Gunnarsson L, Nordberg Karlsson E, Albrekt AS, Andersson M, Holst O, Ohlin M: A carbohydrate binding module as a diversity- carrying scaffold. Protein Eng Des Sel 2004; 17: 213-221.
32. Lefranc MP, Lefranc G: The Immunoglobulin Factsbook. San Diego, Academic Press, 2001.
33. Lefranc MP, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G: IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003; 27: 55-77.
34. Baeckstrom D, Hansson GC, Nilsson O, Johansson C, Gendler SJ, Lindholm L: Purification and characterization of a membrane- bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem 1991; 266: 21537-21547.
35. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF: Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17-21.
36. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47: 5476-5482.
37. Ohlin M, Owman H, Mach M, Borrebaeck CAK: Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol 1996; 33: 47-56.
38. Barrios Y, Knör S, Lantto J, Mach M, Ohlin M: Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein Bspecific antibody results in variants with diverse anti-viral properties. Mol Immunol 2007; 44: 680-690.
39. Daugherty PS, Chen G, Iversson BL, Georgiou G: Quantitative analysis of the effect of the maturation of single chain Fv antibodies. Proc Natl Acad Sci USA 2000; 97: 2029-2034.
40. Persson H, Wallmark H, Ljungars A, Hallborn J, Ohlin M: In vitro evolution of an antibody fragment population to find high-affinity hapten binders. Protein Eng Des Sel 2008; 21: 485-493.
41. Ramirez-Benitez MC, Almagaro JC: Analysis of antibodies of known structure suggests a lack of correspondence between the residues in contact with the antigen and those modified by somatic hypermutation. Proteins 2001; 45: 199-206.
42. Tomlinson IM, Walter G, Jones PT, Dear PH, Sonnhammer EL, Winter G: The imprint of somatic hypermutation on the repertoire of human germline V genes. J Mol Biol 1996; 256: 813-817.
43. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD: Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinitydriven selection. J Mol Biol 1996; 255: 28-43.
44. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, Goletz S: Panko- Mab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006; 55: 1337-1347.